IO Biotech, Inc. (NASDAQ:IOBT) Shares Purchased by XTX Topco Ltd

XTX Topco Ltd raised its position in IO Biotech, Inc. (NASDAQ:IOBT) by 80.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 50,486 shares of the company’s stock after purchasing an additional 22,446 shares during the quarter. XTX Topco Ltd owned about 0.08% of IO Biotech worth $55,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Citadel Advisors LLC acquired a new position in IO Biotech in the 4th quarter valued at about $249,000. Renaissance Technologies LLC boosted its holdings in IO Biotech by 22.5% in the 4th quarter. Renaissance Technologies LLC now owns 118,800 shares of the company’s stock valued at $109,000 after purchasing an additional 21,800 shares during the last quarter. Finally, Dauntless Investment Group LLC acquired a new position in IO Biotech in the 4th quarter valued at about $688,000. 54.76% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have weighed in on the stock. Wall Street Zen upgraded shares of IO Biotech to a “sell” rating in a report on Saturday, June 14th. HC Wainwright reiterated a “buy” rating on shares of IO Biotech in a report on Wednesday, May 14th. Finally, Morgan Stanley decreased their target price on shares of IO Biotech from $6.00 to $4.00 and set an “overweight” rating on the stock in a report on Tuesday.

IO Biotech Stock Performance

IO Biotech stock opened at $2.16 on Friday. The company’s 50 day simple moving average is $1.66 and its 200-day simple moving average is $1.23. The company has a market capitalization of $84.33 million, a price-to-earnings ratio of -1.37 and a beta of 0.44. IO Biotech, Inc. has a 1 year low of $0.66 and a 1 year high of $2.48.

IO Biotech (NASDAQ:IOBT) last released its quarterly earnings results on Thursday, August 14th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05). Equities analysts expect that IO Biotech, Inc. will post -1.35 earnings per share for the current year.

IO Biotech Profile

IO Biotech, Inc, a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer.